Revolutionising allergies diagnostics with the next generation of ultra-sensitiv...
Revolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearls
The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms.
Than...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EUIN2017-87308
DESARROLLO DE UN DISPOSITIVO KET PARA EL DIAGNOSTICO DE ALER...
23K€
Cerrado
RTC-2016-5441-1
DESARROLLO DE UNA PLATAFORMA UNIVERSAL PARA EL DISEÑO Y VALI...
305K€
Cerrado
PRONTO
self-PoweRed cONductimeter for digiTalization of rapid mOlec...
150K€
Cerrado
PTQ-17-09111
Desarrollo de un inmunoensayo ultrasensible y multiplexado p...
57K€
Cerrado
PLEC2021-007972
Amplificación de la polimerasa en combinación con un array e...
200K€
Cerrado
HumanIgE
Identification of long-term therapeutic strategy in IgE-medi...
2M€
Cerrado
Información proyecto Nexdiag
Duración del proyecto: 30 meses
Fecha Inicio: 2023-04-05
Fecha Fin: 2025-10-31
Líder del proyecto
NEXDOT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Descripción del proyecto
The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms.
Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood. This innovation will revolutionize the way allergies are treated by reducing drastically the time to diagnostic and its associated cost (x10-20 reduction).
Our technology could also be extended to serology tests, for detection of patient’s antibodies against infectious agents or cancer markers. It can be extended for global health for the easy and cost-effective detection of antigens as infectious or toxic agents in human, animals or environment for global health, or food for industry.